Liraglutide Effect in Atrial Fibrillation

NCT03856632 on ClinicalTrials.gov · last registry update 2026-05-01

Closed to new participants; the 60 already enrolled are still being followed. Due to report 31 December 2026, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Change in size of Left Atrial Epicardial Adipose Tissue (LAEAT). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 18 March 2019 — 7 years so far. liraglutide is approved in the US, but not for atrial fibrillation — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: ACTIVE_NOT_RECRUITING
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Miami
Sponsor type: Other
Enrollment: 60
Started: 2019-03-18
Primary completion: 2026-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in size of Left Atrial Epicardial Adipose Tissue (LAEAT)

Conditions studied

Atrial Fibrillation

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.